Dr. Tagawa on 2 radiopharmaceuticals for prostate cancer with a proven survival advantage

Video

In this video, Scott T. Tagawa, MD, MS, FACP, discusses the alpha emitter radium-223 dichloride (Xofigo) and the PSMA targeted therapy lutetium Lu 177 vipivotide tetraxetan (Pluvicto), 2 FDA-approved radiopharmaceutical therapies that have proven survival advantages for patients with prostate cancer. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.

Related Videos
Phillip H. Kuo, MD, PhD, FACR, answers a question during a Zoom video interview
blurred image of a clinic hallway
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Dr. Brian F. Chapin in an interview with Urology Times
Dr. Brian F. Chapin in an interview with Urology Times
Brian F. Chapin, MD, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.